Diaceutics PLCLSE: DXRX

Diaceutics: Director/PDMR Shareholding

· Issued by Diaceutics PLC via RNS

Summary by 6ix AI

Diaceutics PLC, which provides diagnostic data and engagement services to biopharma companies, granted 976,744 share options over ordinary shares of £0.002 each to certain directors and senior management on October 23, 2026, under its Employee Share Option Plan.

Key details

  • Executive directors received: CEO Ryan Keeling 301,625 options (1,640,923 shares under option after the grant, 1.92% of existing issued share capital), CFO Nick Roberts 195,861 (815,196; 0.96%) and Jordan Clark 191,508 (521,005; 0.61%).
  • Senior managers received: Sandra Blake 93,144 options (255,730 in total; 0.30%), Chris Meenan 106,668 (106,668; 0.13%) and Susanne Munksted 87,938 (412,911; 0.48%).
  • The exercise price is £0.002 per share, equal to the shares' nominal (face) value.
  • Executive directors' options vest on a sliding scale up to 100%, based on growth over 3 years from July 30, 2026 in total shareholder return, revenue compound annual growth rate and adjusted EBITDA margin (a profit measure). Other employees' options vest after three years from grant, dependent on continued employment and satisfactory performance.
  • After the grant, 7,042,578 share options are outstanding, approximately 8.26% of the current issued share capital of 85,291,958 shares.

What’s still pending

  • Vesting of the executive directors' options is subject to meeting the performance criteria; other employees' options depend on continued employment and satisfactory performance.
  • The Remuneration Committee will review the performance conditions periodically and keeps discretion to amend them.

6ix AI wrote this summary from the release below and checked it against the release.

Diaceutics PLC
12 November 2026

Diaceutics PLC

Grant of Share Options/PDMR Shareholdings

New York, Belfast and London, 12 November 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, announces the grant of 976,744 share options over ordinary shares of £0.002 each in the Company (“Share Options”) to certain directors and members of the Company’s senior management team on 23 October 2026, pursuant to the Company’s Employee Share Option Plan (“ESOP”). These awards are made in accordance with the Company’s long term incentive plan as detailed in the Company’s Annual Report.

Share Options were granted as follows:

Name

Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Performance Period

Ryan Keeling, CEO

301,625

1,640,923

1.92%

3 years from 30 July 2026

Nick Roberts, CFO

195,861

815,196

0.96%

3 years from 30 July 2026

Jordan Clark, CCO

191,508

521,005

0.61%

3 years from 30 July 2026

Sandra Blake, CMPO and PDMR

93,144

255,730

0.30%

3 years from 30 July 2026

Chris Meenan, CPTO and PDMR

106,668

106,668

0.13%

3 years from 30 July 2026

Susanne Munksted, CPO and PDMR

87,938

412,911

0.48%

3 years from 30 July 2026

For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return (“TSR”), the revenue Compound Annual Growth Rate (“CAGR”) and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.

The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.

The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 7,042,578 representing approximately 8.26% of its current issued share capital of 85,291,958.

Enquiries:

Diaceutics PLC

Ryan Keeling, Chief Executive Officer

Tel: +44 (0)28 9040 6500

Nick Roberts, Chief Financial Officer

investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Tel: +44 (0)20 7253 8000

Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Diaceutics PLC on 6ix

Story so far

Earlier from Diaceutics

All Diaceutics news releases